September 28, 2026
WBD shareholders face a longer wait than the deal anticipated.
Analyst Targets
- Consensus: Hold, average 12-month target roughly $30.17, range $26 to $31.25 (Investing.com, 12 analysts)
- Deal floor: $31.00 per share cash, the agreed Paramount acquisition price
- Ticking fee: $0.25 per share per quarter (measured daily) after September 30, 2026
What Changed This Week
The settlement that was supposed to clear the last regulatory checkbox for Paramount’s acquisition of Warner Bros. Discovery did not get blessed. It got questioned, hard.
The #1 Commodity Trade of 2026
Gold bugs are going to hate this. The #1 commodity trade of 2026 isn’t gold, silver, oil, or any rare earth metal. It’s something far more valuable – something The New York Times says “powers the world’s tech.”
And America controls over 80% of the world’s supply. When Trump restricts exports, Morgan Stanley estimates it could trigger a $10 trillion boom. And you have the rare opportunity to get in on the ground floor.
On September 24, Judge Araceli Martínez-Olguín held a virtual hearing on the consent decree that Paramount and 12 state attorneys general reached earlier in the week. She made the posture plain: the court is not a rubber stamp. She deferred her ruling to an unspecified point “in due course” and set one immediate deadline: parties must respond by noon PT today, September 28, to a letter from Senator Cory Booker urging an independent public-interest review of the settlement before it is entered.
Before the hearing even began, Judge Martínez-Olguín granted the Block the Merger coalition’s emergency motion to file amicus briefs, with a hard cutoff of 12:01 a.m. PT on September 25. Those briefs are now in. The coalition, which includes Free Press, the Committee for the First Amendment, the Freedom of the Press Foundation, the Future Film Coalition, and the International Documentary Association, argues the consent decree is weak and unenforceable. LULAC filed separately to the same effect.
The Structural Problem for WBD Holders
What WBD shareholders own today is an arbitrage position with a legally mandated floor and a legally mandated ceiling, but no fixed close date. Paramount agreed not to close or integrate the acquisition until five days after a ruling after the March 2027 trial, or June 1, 2027, whichever comes first. The trial runs March 2 through March 19. That is about five months away.
The Overlooked SpaceX Play
The opportunity right now is NOT to buy SpaceX – it’s to own the small, overlooked stocks that could rip triple digits as Elon expands his empire. That’s according to Tim Bohen, self-made millionaire who called Tesla at $37.
The ticking fee clock starts tomorrow. Under the merger agreement, Paramount owes WBD shareholders $0.00277778 per share per day beginning October 1. Those payments are not due until closing, which means WBD holders carry the uncertainty while Paramount carries the accrual.
Booker’s letter, filed in his capacity as Ranking Member of the Senate Judiciary Subcommittee on Antitrust, Competition Policy, and Consumer Rights, argued that the settlement reached the court without a competitive impact statement, without a public comment period, and without any formal opportunity for theaters, distributors, workers, or consumers to be heard. Paramount called it an improper “pseudo-amicus submission.” The judge asked for answers anyway.
Forward Scenarios
Bull
Judge Martínez-Olguín approves the consent decree promptly after today’s party responses, the settlement holds, and the deal closes well before the March trial date. WBD shareholders collect the $31 cash price plus whatever ticking fee has accrued. At today’s price near $30.86, that is a modest premium with downside protection. The ticking fee provides a rising floor for every additional day of delay.
Base
The judge withholds settlement approval and the case proceeds toward the March 2027 trial. The deal remains legally alive, Paramount is bound not to close before the court’s merits decision (or June 1, 2027), but close is delayed past the originally expected Q3 2026 target by at least several months. WBD trades in a narrow band below $31, with price compressed by deal-close uncertainty and macro media-sector pressure. Ticking fees accumulate but do not catalyze a re-rating until a trial outcome emerges.
Get Into Anthropic Before the IPO
Anthropic is heading for a huge AI IPO.
A little-known public company already owns nearly 1% of it.
Because the shares are already trading, there’s no six-month lockup.
You could position yourself now and decide later whether to hold or sell on day one.
Bear
The judge rejects the settlement outright, the March trial produces an injunction blocking the merger, and Paramount invokes the $7 billion regulatory termination fee rather than pursue a blocked deal. WBD stock loses its acquisition premium entirely, reverting toward standalone fundamentals. The 52-week low is $17.07, roughly 45% below the deal price, and the company still carries substantial legacy debt.
Technical Overlay
WBD is trading around $30.86 Monday morning, sitting roughly $0.14 below the $31 deal price. The gap between current price and deal price is the market’s implied probability discount on close. The 52-week high is $30.92. Any settlement approval would likely close that gap quickly; any trial-blocking outcome would gap the stock sharply lower toward the mid-$20s at minimum.
Bottom Line
The question for WBD holders is not whether the $31 price is real. It is contractually real, ticking fee and all. The question is what the probability-weighted expected value of holding this position is through a March 2027 trial. Judge Martínez-Olguín’s tone last Thursday was not hostile to the deal’s existence but was plainly hostile to the consent decree’s process. Today’s party responses to Senator Booker are the next inflection point. If the judge signals approval is imminent, the spread compresses fast. If she schedules further briefing, the base case extends and the stock likely drifts lower, with the ticking fee as the only upward pull.
